Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug
Synopsis
New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.
Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Pemvidutide is a drug that targets both GLP-1 and glucagon receptors and is used to treat liver diseases.
The company said that the 48-week data showed statistically significant improvements versus placebo in key non-invasive liver tests, including enhanced liver fibrosis and liver stiffness, with continued progress from week 24. The higher dose also delivered additional weight loss without signs of plateauing, while maintaining a favorable safety profile.
Altimmune also said it held a productive End-of-Phase 2 meeting with the FDA, aligning on plans for a registrational Phase 3 trial.
ALT was the top-trending tickers on Stocktwits at the time of writing.
Get updates to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.